Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion

Background. To evaluate the efficacy of intravitreal bevacizumab (IVB) injection with or without macular laser photocoagulation (MLP) for recurrent or persistent macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods. Thirty-four eyes underwent IVB injection for ME secondary t...

Full description

Saved in:
Bibliographic Details
Main Authors: Takafumi Hirashima, Tomoyuki Chihara, Toshitaka Bun, Takao Utsumi, Miou Hirose, Hideyasu Oh
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2014/173084
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849308152762204160
author Takafumi Hirashima
Tomoyuki Chihara
Toshitaka Bun
Takao Utsumi
Miou Hirose
Hideyasu Oh
author_facet Takafumi Hirashima
Tomoyuki Chihara
Toshitaka Bun
Takao Utsumi
Miou Hirose
Hideyasu Oh
author_sort Takafumi Hirashima
collection DOAJ
description Background. To evaluate the efficacy of intravitreal bevacizumab (IVB) injection with or without macular laser photocoagulation (MLP) for recurrent or persistent macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods. Thirty-four eyes underwent IVB injection for ME secondary to BRVO as a primary treatment. Twenty of the 34 eyes experienced recurrent or persistent ME after the first IVB. Nine of the 20 eyes (Group 1) were retreated with IVB combined with MLP. The remaining 11 eyes (Group 2) were retreated with IVB alone. Results. In Group 1, the postoperative best corrected visual acuity (BCVA) improved compared with the preoperative value at all follow-up visits, although no statistically significant improvement was observed at 6 months. In contrast, BCVA significantly improved from 0.53 to 0.40 at 6 months (P<0.05) in Group 2. Conclusion. Combined therapy tended to have a smaller effect on visual acuity compared with IVB monotherapy.
format Article
id doaj-art-1454740d2c724626a24bc5ed6d85bfce
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-1454740d2c724626a24bc5ed6d85bfce2025-08-20T03:54:33ZengWileyJournal of Ophthalmology2090-004X2090-00582014-01-01201410.1155/2014/173084173084Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein OcclusionTakafumi Hirashima0Tomoyuki Chihara1Toshitaka Bun2Takao Utsumi3Miou Hirose4Hideyasu Oh5Department of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanDepartment of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanDepartment of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanDepartment of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanDepartment of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanDepartment of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, JapanBackground. To evaluate the efficacy of intravitreal bevacizumab (IVB) injection with or without macular laser photocoagulation (MLP) for recurrent or persistent macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods. Thirty-four eyes underwent IVB injection for ME secondary to BRVO as a primary treatment. Twenty of the 34 eyes experienced recurrent or persistent ME after the first IVB. Nine of the 20 eyes (Group 1) were retreated with IVB combined with MLP. The remaining 11 eyes (Group 2) were retreated with IVB alone. Results. In Group 1, the postoperative best corrected visual acuity (BCVA) improved compared with the preoperative value at all follow-up visits, although no statistically significant improvement was observed at 6 months. In contrast, BCVA significantly improved from 0.53 to 0.40 at 6 months (P<0.05) in Group 2. Conclusion. Combined therapy tended to have a smaller effect on visual acuity compared with IVB monotherapy.http://dx.doi.org/10.1155/2014/173084
spellingShingle Takafumi Hirashima
Tomoyuki Chihara
Toshitaka Bun
Takao Utsumi
Miou Hirose
Hideyasu Oh
Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
Journal of Ophthalmology
title Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
title_full Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
title_fullStr Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
title_full_unstemmed Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
title_short Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion
title_sort intravitreal bevacizumab alone or combined with macular laser photocoagulation for recurrent or persistent macular edema secondary to branch retinal vein occlusion
url http://dx.doi.org/10.1155/2014/173084
work_keys_str_mv AT takafumihirashima intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion
AT tomoyukichihara intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion
AT toshitakabun intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion
AT takaoutsumi intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion
AT miouhirose intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion
AT hideyasuoh intravitrealbevacizumabaloneorcombinedwithmacularlaserphotocoagulationforrecurrentorpersistentmacularedemasecondarytobranchretinalveinocclusion